Advanced NSCLC: New cytostatic agents

Lung Cancer

Volumn 41, Issue SUPPL. 1, 2003, Pages 123-132

  Kosmidis, Paris A ^a   Manegold, Christian ^b  

^a HYGEIA HOSPITAL   (Greece)

^b Thoraxklinik   (Germany)

Author keywords

Cytostatic agents; Non small cell lung cancer; Oxaliplatin, epothilones, irinotecan and alimta

Indexed keywords

CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYANOCOBALAMIN; CYTOSTATIC AGENT; DEXAMETHASONE; DOCETAXEL; EPOTHILONE A; EPOTHILONE B; EPOTHILONE DERIVATIVE; FOLIC ACID DERIVATIVE; GEMCITABINE; IRINOTECAN; IXABEPILONE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; VINDESINE;

ADVANCED CANCER; ALOPECIA; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; BONE MARROW SUPPRESSION; CONFERENCE PAPER; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DYSESTHESIA; FATIGUE; GRANULOCYTOPENIA; HEMATOLOGIC DISEASE; HUMAN; HYPERSENSITIVITY REACTION; INFECTION; INFORMATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MELANOMA; MUCOSA INFLAMMATION; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; SEPSIS; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 0038012200     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(03)00156-9     Document Type: Conference Paper

References (69)

1. Burchenal J.H., Kalaher K., Dew K., et al. Rationale for development of platinum analogs. Cancer Treat. Rep. 63:1979;1493-1497.
2. Misser J.L., Bleiberg H., Sutherland W., et al. Oxaliplatin clinical activity: a review. Crit. Rev. Oncol. Hematol. 35:2000;75-93.
3. Perez R.P. Cellular and molecular determination of cisplatin resistance. Eur. J. Cancer. 34:1998;1535-1542.
4. Nehme A., Baskaran R., Nebel S., et al. Introduction of JNK and C-ABI signaling by cisplatin and oxaliplatin in mismatch repair-proficient and-deficient cells. Br. J. Cancer. 79:1999;1104-1110.
5. Raymond E., Lawrence R., Izbicka E., et al. Activity of oxaliplatin against human tumor colony-forming units. Clin. Cancer Res. 4:1998;1021-1029.
6. Rixe O., Ortuzar W., Alvarez M., et al. Oxaliplatin, terraplatin, cisplatin and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's anticancer drug screen panel. Biochem. Pharmacol. 52:1996;1855-1865.
7. Extra J.M., Espie M., Calvo M., et al. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother. Pharmacol. 25:1990;299-303.
8. Monnet I., Brienza S., Hugret F., et al. Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer. Eur. J. Cancer. 34:1998;1124-1127.
9. De Cremoux H., Bekradda M., Monet I., et al. Update of the oxaliplatin/navelbine phase I/II multicentric trial in patients with advanced non-small cell lung cancer. Ann. Oncol. (Abstract). 9:1998;98.
10. Franciosi V., Barbieri R., Vasini G., et al. The combination of gemcitabine and oxaliplatin (GEM-OXAL) is feasible in patients with poor prognosis advanced non-small cell lung cancer. Results of a phase II study. Eur. J. Cancer. 37:2001;6.
11. Bollag D.M., McQueney P.A., Zhu J., et al. Epothilones, a new class of microtubule stabilizing agents with a taxol-like mechanism of action. Cancer Res. 55:1995;2325-2333.
12. Kowalski R.J., Giannakakou P., Homel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (taxol). J. Biol. Chem. 272:1997;2534-2541.
13. Lee F.Y.F., Borzilleri R., Fairchild C.R., et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin. Cancer Res. 7:2001;1429-1437.
14. Calvert PM, O'Neill V, Twelves C, et al. A phase I clinical and pharmacokinetic study of EPO906 (epothilone B), given every 3 weeks in patients with solid tumors, Proc Am Soc Clin Oncol 2001;429 (Abstract).
15. Rubin EH, Sin LL, Moore MJ, et al. A phase I and pharmacologic trial of weekly epothilone B in patients with advanced malignancies, Proc Am Soc Clin Oncol 2001;270 (Abstract).
16. Spriggs D, Soignet S, Bienvenu B, et al. Phase I first in main study of the epothilone B analog BMS-247550 in patients with advanced cancer, Proc Am Soc Clin Oncol 2001;42 (Abstract).
17. LoRusso PM, Wozniak AJ, Flaherty LE, et al. Phase I clinical trial of BMS-247550 in adult patients with advanced solid tumors, Proc Am Soc Clin Oncol 2001;2125 (Abstract).
18. Awada A, Bleiberg H, De Valeriola D, et al. Phase I clinical and pharmacology study of the epothilone analog BMS-247550 given weekly in patients with advanced solid tumors, Proc Am Soc Clin Oncol 2001;427 (Abstract).
19. Hao D., Hammond L.A., Berg K.E., et al. A phase I and pharmacokinetic study of BMS-247550, an epothilone-B analog given on a continuous weekly schedule in patients with advanced malignancies. Proceedings of the 12th NCI-EORTC AACR Symposium. Clin. Cancer Res. 7:2001;785. abst.
20. Mani S, McDaid H, Shen HJ, et al. Phase I evaluation of an epothilone B analog BMS-247550: clinical findings and molecular correlates, Proc Am Soc Clin Oncol 2001;269 (Abstract).
21. Fojo AT, Kotz H, Abroham J, et al. A phase I clinical trial of BMS-247550 an epothilone B analogue in patients with refractory neoplasms. Proceedings of the 12th NCI-EORTC AACR Symposium, Clin Cancer Res 2001;7:774 (Abstract).
22. Verweij J., Schellens J.H.M. Topoisomerase I inhibition: a new target or new missils. Editorial Ann. Oncol. 6:1995;102-104.
23. Rothenberg M.L. Topoisomerase I inhibitors: review and update. Ann. Oncol. 8:1997;837-855.
24. Masumoto N., Nakano S., Esaki T., et al. Inhibition of cis-diamminedichloroplatinum (II) induced DNA interstrand cross-link ranoval by 7-ethyl-10-hydroxyl-camptothecin in HST-1 human squamous carcinoma cells. Int. J. Cancer. 62:1995;70-75.
25. Pei X.H., Nakanishi Y., Takayama K., et al. Effect of CPT-11 in combination with other anticancer agents in lung cancer cells. Anticancer Drugs. 8:1997;231-237.
26. Negoro S., Fukuoka M., Niitani H., et al. A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group. Gan To Kagaku Ryoho. 18:1991;1013-1019.
27. Fukuoka M., Niitani H., Suzuki A., et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J. Clin. Oncol. 10:1992;16-20.
28. Douillard J., Ibrahim N., Riviere A., et al. Phase II study of CPT-11 (irinotecan) in non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 14:1995;365. Abstract #1118.
29. Baker L., Khan R., Lynch T., et al. Phase II study of irinotecan (CPT-11) in advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 16:1997;461a. Abstract #1658.
30. Masuda N., Fukuoka M., Takada M., et al. CPT-11 in combination with cisplatin for advanced non-small cell lung cancer. J. Clin. Oncol. 10:1992;1775-1780.
31. Ueoka H., Tanimoto M., Kiura K., et al. Fractionated administration of irinotecan and cisplatin for treatment of non-small cell lung cancer: a phase II study of Okayama Lung Cancer Study Group. Br. J. Cancer. 85:2001;9-13.
32. Mori K., Machida S., Yoshida T., et al. A phase II study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support for advanced non-small cell lung cancer. Cancer Chemother. Pharmacol. 43:1999;467-470.
33. Cardenal F., Domine M., Massuti B., et al. Multi-institutional phase II study of an intensive single dose of irinotecan (CPT-11) and cisplatin (CDDP) every 3 weeks, in patients with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 19:2000;534a. Abstract #2100.
34. Wagner H., Faderl B., Dankelmann E., et al. Phase II study of irinotecan in combination with cisplatin as first line chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 18:1999;527a. Abstract #2032.
35. DeVore R.F., Johnson D.H., Crawford J., et al. Phase II study of irinotecan plus cisplatin in patients with advanced non-small cell lung cancer. J. Clin. Oncol. 17:1999;2710-2720.
36. Jagasia M.H., Langer C.J., Johnson D.H., et al. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study. Clin. Cancer Res. 7:2001;68-73.
37. Mukohara T., Takeda K., Migazaki M., et al. Phase II study of irinotecan (CPT-11) and carboplatin (CBDCA) in advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 19:2000;534a. Abstract #2101.
38. Kinoshita A., Fukuda M., et al. A phase II study of irinotecan (CPT 11) and carboplatin (CBDCA) in patients (pts) with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 20:2001;268b. Abstract #2823.
39. Langer C.J. Irinotecan/taxane combinations in advanced non-small cell lung cancer. Clin. Lung Cancer. 4:(Suppl. 1):2002;S10-S14.
40. Socinski M.A. Irinotecan in non-small cell lung cancer: status of ongoing trials. Clin. Lung Cancer. 4:(Suppl. 1):2002;S15-S20.
41. Bunn P.A. Jr. The role of irinotecan combined with cisplatin or carboplatin in the treatment of advanced non-small cell lung. Cancer. 4:(Suppl. 1):2002;S5-S7.
42. Niho S., Nagao K., Nishiwaki Y., et al. Randomized multicenter phase III trial of irinotecan (CPT-11) and cisplatin (CDDP) versus CDDP and vindesine (VDS) in patients with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 18:1999;492a. Abstract #1897.
43. Masuda N., Fukuoka M., Negoro S., et al. Randomized trial comparing cisplatin (CDDP) and irinotecan (CPT-11) versus CDDP and vindesine (VDS) versus CPT-11 alone in advanced non-small cell lung cancer (NSCLC), a multicenter phase III study. Proc. Am. Soc. Clin. Oncol. 18:1999;459a. Abstract #1774.
44. Takeda K., Yamamoto N., Negoro S., et al. Randomized phase II study of docetaxel (DOC) plus cisplatin (CDDP) versus DOC plus irinotecan in advanced non-small cell lung cancer (NSCLC); a West Japan Thoracic Oncology Group (WJTOG) study. Proc. Am. Soc. Clin. Oncol. 19:2000;497a. Abstract #1944.
45. Nagao K., Fukuoka M., Fujita A., et al. A phase II study of irinotecan combined with cisplatin in non-small cell lung cancer. CPT-11 Lung Cancer Study Group. Jpn. J. Cancer Chemother. 27:2000;413-421.
46. Kakolyris S., Kouroussis C., Kalbakis K., et al. Salvage treatment of advanced non-small cell lung cancer previously treated with docetaxel-based front-line chemotherapy with irinotecan (CPT-11) in combination with cisplatin. Ann. Oncol. 11:2000;757-760.
47. Nakanishi Y., Takayama K., Takano K., et al. Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer. Am. J. Clin. Oncol. 22:1999;399-402.
48. Shih C., Thornton D.E. Preclinical pharmacology studies and the clinical development of a novel multi-targeted antifolate, MTA (LY231514). Jackman A.L. Antifolate drugs in cancer therapy. 1999;183-201 Humana Press, Totowa, NJPG.
49. Schultz R.M., Patel V.F., Worzalla J.F., et al. The role of thymidylate synthase in the antitumor activity of the multi-targeted antifolate, LY231514. Anticancer Res. 19:1999;437-443.
50. Shih C., Chen V.J., Gossett L.S., et al. LY231514, a pyrrolo (2, 3-D) pyrimidine-based antifolate led inhibits multiple folate-requirering enzymes. Cancer Res. 57:1997;1116-2011.
51. Woodland J.M., Barnett C.J., Dorman D.E., et al. Metabolism and disposition of the antifolate LY231514 in mice and dogs. Drugs Metab. Dispos. 25:1997;693-700.
52. McDonald A.C., Vasey P.A., Adams L., et al. A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin. Cancer Res. 4:(3):1998;605-610.
53. Rinaldi D.A., Kuhn J.G., Burris H.A., et al. A phase I evaluation of multitargeted antifolate (MTA, LY 231514) administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother. Pharmacol. 44:1999;372-380.
54. Rinaldi D.A., Burris H.A., Dorr F.A., et al. Initial phase I evaluation of the novel thymidylate synthase inhibitor; LY231514, using the modified continual reassessment method for dose escalation. J. Clin. Oncol. 13:(11):1995;2842-2850.
55. Thoedtmann R., Depenbrock H., Dumez H., et al. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY 231514) in combination with cisplatin. J. Clin. Oncol. 17:1999;3009-3016.
56. Hughes A., Calvert P., Azzabi A., et al. Phase I clinical and pharmacokinetics study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J. Clin. Oncol. 20:2002;3533-3544.
57. Adjei A.A., Erlichman C., Sloan J.A. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J. Clin. Oncol. 18:2000;1748-1757.
58. Niyikiza C., Walling J., Thornton D., et al. MTA (LY 231514): relationship of vitamin metabolite profile, drug exposure and other patient characteristics to toxicity. Ann. Oncol. 9:1998;126-134.
59. Calvert H. Folate status and the safety profile of antifolates. Semin. Oncol. 29:(Suppl. 5):2002;3-7.
60. Bunn P., Paoletti P., Niyikiza C., et al. Vitamin B12 and folate reduce toxicity of pemetrexed (LY231514, MTA) a novel antifolate/antimetabolite. Proc. ASCO. 20:2001;76a. Abstract 300.
61. Clarke S, Boyer M, Millward M. Phase II study of LY231514 in patients with advanced non-small cell lung cancer, Proc ASCO 1997;16 (Abstract 465).
62. Rusthoven J.J., Eisenhower E., Butts C., et al. Multi-targeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small cell lung cancer: a phase II study. J. Clin. Oncol. 17:1999;1194-1199.
63. Postmus P.E., Green M.R. Overview of MTA in the treatment of non-small cell lung cancer. Semin. Oncol. 26:(Suppl. 4):1999;31-36.
64. Shin D.M., Scagliotti G., Kindler H., et al. A phase II trial of pemetrexed in malignant pleural mesothelioma (MPM) patients: clinical outcome, role of vitamin supplementation, respiratory symptoms and lung function. Proc. ASCO. 21:2002;294a. Abstract 1175.
65. Manegold C., Gatzemeier U., von Pawel J., et al. Front-line treatment of advanced non-small cell lung cancer with MTA (LY231514, pemetrexed disodium, pemetrexed ‰) and cisplatin: a multi-center phase II trial. Ann. Oncol. 11:2000;435-440.
66. Shepherd F., Dancey J., Arnold A., et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced non-small cell lung carcinoma. Cancer. 93:2001;595-600.
67. Monnerat C., Le Chevalier T., Novello S., et al. Clinical results from a phase II trial of pemetrexed+gemcitabine in advanced non-small lung cancer. Ann. Oncol. 13:(Suppl. 5):2002;132. Abstract 483 PD.
68. Vogelzang N.J., Rusthoven J., Paoletti P., et al. Phase III single-blinded study of pemetrexed plus cisplatin versus cisplatin alone in chemo-naive patients with malignant pleural mesothelioma. Proc. ASCO. 21:2002;2a. Abstract 5.
69. Liepa A., Rusthoven J., Denham C., et al. Clinical benefit algorithm for malignant pleural mesothelioma: results from randomized trial of pemetrexed plus cisplatin versus cisplatin. Ann. Oncol. 13:(Suppl. 5):2002;129. Abstract 475 PD.